The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation (NCT01217619, ESTERN).
Baohui Han
No relevant relationships to disclose
Liwen Xiong
No relevant relationships to disclose
Jiayuan Sun
No relevant relationships to disclose
Rong Li
No relevant relationships to disclose
Yuqing Lou
No relevant relationships to disclose
Yanwei Zhang
No relevant relationships to disclose